To the Editor: Plasmacytoid dendritic cells (pDCs) produce inflammatory cytokines upon infection with various pathogens, but can also induce production of Foxp3 þ regulatory T cells (T reg ). 1 Recently, Lombardi et al. 2 reported that expression of the a-and b-subunits of CD8 could be used to differentiate three stable subsets of pDC. The subsets expressing CD8a alone or in combination with CD8b were tolerogenic, inducing T reg cells in a mouse model of airway hyperreactivity, whereas CD8a À b À pDC were immunogenic, robustly secreting inflammatory cytokines that exacerbated disease. 2 In contrast to these results, we found that CD8 expression by mature pDC is not stable but, rather, is inducible after toll-like receptor (TLR) stimulation, thereby indicating that CD8 expression does not delineate discrete and (Figure 1a) . In response to either CpG or R848, a significant proportion of CD8a À b À pDCs upregulated both CD8a and CD8b expression (Figure 1a and b) . To determine whether the increase in expression of CD8a and CD8b was associated with cellular activation, we assessed the expression of major histocompatibility complex (MHC) class II and mPDCA-1, both of which are upregulated upon activation of pDCs. 1, 3, 4 CD8a þ b þ pDCs from the cells cultured with CpG (Figure 1c) or R848 (not shown) had greatly elevated levels of both MHC class II and mPDCA-1 compared with CD8a À b À pDCs in the same cultures or cultured in media alone. Furthermore, we found using an IL12p40-yellow fluorescent protein reporter mouse that expression of IL12p40 following CpG stimulation was restricted to CD8a þ pDC (Figure 1d ) with little interleukin (IL)12 produced directly by CD8a À pDCs (Figure 1d ). There have been other reports of pDCs modulating expression of CD8a upon stimulation with TLR agonists. 3, 4 Therefore, we suggest that expression of CD8 subunits by pDC mirrors cellular activation rather than defining stable mature subsets with different activities. Lombardi et al.
LETTER TO THE EDITOR
2 observed differential cytokine expression by CD8-expressing pDCs. This may be because CD8-expressing pDC had been activated prior to treatment in vitro with agonists and thus were partially ''exhausted'' and unable to be fully restimulated to produce cytokines. Whether the pDC acquire a tolerogenic phenotype after their initial activation and upregulation of CD8a/b remains to be fully elucidated.
